SBIR/STTR Research Award
Oral Dietary Supplement for U.S. Navy Dolphins
Award amount
$1,132,082Program and phase
SBIR · Phase IIAward year
2021Award details
- Awarding agency
- Department of Defense
- Branch
- Navy
- Recipient company
- EPITRACKER INC
- Proposal award date
- 2021-06-23
- Contract end date
- 2023-06-22
- UEI
- UQNNE3H22VP8
- Solicitation number
- 18.2
- Topic code
- N182-128
Research abstract
The Scope of this Phase II SBIR is to assess safety, pharmacokinetics, efficacy and scaleup of four lead micronutrients (ETI-101, ETI-070, ETI-1005 and ETI-1023) that were identified during Phase I and may be advanced as novel oral supplements to protect health in aging Navy dolphins, especially in the areas of hematological, immune, and metabolic health. The Phase II Base period (24 months) will focus on in vitro and in vivo screening of our compounds using standard laboratory assays and models, as well as initial scaleup of the selected lead compound. The Phase II Option period (24 months) will focus on larger scaleup and encapsulation of the lead compound, as well as safety and efficacy field studies.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
2 SBIR/STTR records share this UEI (2019–2021). Reported award amounts total $1,256,570. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Defense